Search

Displaying results 1921 - 1930 of 2507 in total
  1. Drug

    Zongertinib

    go.drugbank.com/drugs/DB18762
    ApprovedInvestigational

    Zongertinib is a selective, irreversible tyrosine kinase inhibitor that targets human epidermal growth factor receptor 2 (HER2). It covalently binds to the HER2 receptor, including exon 20 insertions, and inhibits downstream signaling pa...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  2. Drug

    Deuruxolitinib

    go.drugbank.com/drugs/DB18847
    ApprovedInvestigational

    Deuruxolitinib is a deuterated form of ruxolitinib that selectively inhibits Janus kinases (JAK) JAK1 and JAK2. Deuteration allows the drug to circumvent extensive oxidative metabolism around the cyclopentyl ring, which increases the dur...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  3. Drug

    Sunvozertinib

    go.drugbank.com/drugs/DB18925
    Investigational

    Sunvozertinib is an irreversible and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. EGFR is a transmembrane protein with cytoplasmic kinase activity commonly expressed by non-small cell lung carcinomas (NSCL...

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  4. Drug

    Suzetrigine

    go.drugbank.com/drugs/DB18927
    ApprovedInvestigational

    Suzetrigine is a NaV1.8 voltage-gated sodium channel blocker with analgesic properties NaV1.8 is abundantly expressed in peripheral sensory nerves to play a role in pain signal transmission, making it a desirable therapeutic target for t...

    Categories: P-glycoprotein substrates, Cytochrome P-450 CYP2B6 Inducers
  5. Drug

    Orforglipron

    go.drugbank.com/drugs/DB18964
    ApprovedInvestigational

    Orforglipron is a first-in-class oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist. Developed to circumvent the adherence barriers and strict administration requirements of peptide-based GLP-1 therapies, its small-molecu...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates
  6. Drug

    Baxdrostat

    go.drugbank.com/drugs/DB19090
    ApprovedInvestigational

    Baxdrostat is an orally bioavailable, highly selective, first-in-class small-molecule aldosterone synthase inhibitor (ASI) designed to block the production of aldosterone . It targets aldosterone excess, a primary underlying driver of tr...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  7. Drug

    Lanepitant

    go.drugbank.com/drugs/DB19599
    Experimental

    The usage of the INN stem '-pitant' in the name indicates that Lanepitant is a neurokinin NK1​ (substance P) receptor antagonist. Lanepitant has a monoisotopic molecular weight of 559.35 Da.

  8. Drug

    Fosfluconazole

    go.drugbank.com/drugs/DB19833
    Experimental

    Fosfluconazole is a small molecule drug. Fosfluconazole has a monoisotopic molecular weight of 386.07 Da.

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  9. Drug

    Ditekiren

    go.drugbank.com/drugs/DB19992
    Experimental

    Ditekiren is a small molecule drug. The usage of the INN stem '-kiren' in the name indicates that Ditekiren is a renin inhibitor. Ditekiren has a monoisotopic molecular weight of 929.57 Da.

    Categories: P-glycoprotein substrates
  10. Drug

    Lascufloxacin

    go.drugbank.com/drugs/DB20002
    Experimental

    Lascufloxacin is a small molecule drug. The usage of the INN stem '-oxacin' in the name indicates that Lascufloxacin is a nalidixic acid derivative antibacterial. Lascufloxacin has a monoisotopic molecular weight of 439.17 Da.

    Categories: P-glycoprotein substrates